Women's Health: Worldwide Prescription Drug Markets

Published by: Kalorama Information

Published: Feb. 1, 2009 - 336 Pages

Table of Contents

• Scope and Methodology
  
• Size and Growth of the Market
  
• Total Market Size and Forecast
  
• Market Outlook

• History of Women’s Health
  
• Female Reproductive System
  
• Hormone Regulation
  
• Market Trends
  
  
  • Women’s Health Initiative
    
  • Women’s Health Office Act of 2007
    
  • Perimenopausal Use of Contraceptives
    
  • Insurance Coverage for Contraceptives
    
  • Oral Contraceptives in Japan
    
  • Ovarian Cancer Test
    
  • Estrogen Labeling
    
  • Osteoporosis Drug Opportunities in Asia
    
  • Women’s Healthcare Access
  
  
• Demographics

• Overview
  
• Prevalence
  
• Chronic Fatigue Syndrome
  
• Treatment
  
• Fibromyalgia
  
• Treatment
  
• Rheumatoid Arthritis
  
• Treatment
  
• Scleroderma
  
• Treatment
  
• Sjogren’s Syndrome
  
• Treatment
  
• Systemic Lupus Erythematosus
  
• Treatment
  
• Market Size and Growth
  
• Geographical Market Analysis
  
• Research and Development
  
  
  • Ampligen
    
  • Actemra
    
  • Apilimod
    
  • Arcoxia
    
  • Cimza
    
  • Denosumab
    
  • INCBO18424
    
  • Interleukin (IL-1)
    
  • LymphoStat-B
    
  • Milnacipran
    
  • Prestara
    
  • Riquent
    
  • Veldona
  
  
• Competitive Market

• Overview
  
• Incidence and Mortality
  
• Breast Cancer
  
• Overview
  
• Treatment
  
• Cervical Cancer
  
• Overview
  
• Treatment
  
• Endometrial Cancer
  
• Overview
  
• Treatment
  
• Ovarian Cance
  
• Overview
  
• Treatment
  
• Vaginal Cancer
  
• Overview
  
• Treatment
  
• Market Size and Growth
  
• Geographical Market Analysis
  
• Research and Development
  
• Advexin
  
• Alvespimycin
  
• Arzoxifene
  
• Avastin
  
• Axtinib
  
• Cervarix
  
• Herceptin
  
• Karenitecin
  
• Pazopanib
  
• Pertuzumab
  
• Tykerb
  
• Yondeli
  
• Competitive Market

• Overview
  
• Incidence and Prevalence
  
• AIDS
  
  
  • Overview
    
  • Treatment
    
  • Agenerase
    
  • Aptivus
    
  • Combivir
    
  • Crixivan
    
  • Entriva
    
  • Fortovase
    
  • Fuzeon
    
  • Hivid
    
  • Intelence
    
  • Invirase
    
  • Isentress
    
  • Kaletra
    
  • Kivexa
    
  • Lexiva
    
  • Prezista
    
  • Rescriptor
    
  • Reyataz
    
  • Selzentry
    
  • Sustiva
    
  • Trizivir
    
  • Truvada
    
  • Viracept
    
  • Viramune
  
  
• Bacterial Vaginosis
  
• Overview
  
• Treatment
  
• Cervical Dysplasia
  
• Overview
  
• Treatment
  
• Chlamydia
  
• Overview
  
• Treatment
  
• Condyloma Acuminata
  
• Overview
  
• Treatment
  
• Aldara
  
• Alferon N Injection
  
• Condylox
  
• Gardasil
  
• Genital Herpes
  
• Overview
  
• Treatment
  
• Zovirax
  
• Gonorrhea
  
• Overview
  
• Treatment
  
• Hepatitis
  
• Overview
  
• Treatment
  
• Baraclude
  
• Pelvic Inflammatory Disease
  
• Overview
  
• Treatment
  
• Syphilis
  
• Overview
  
• Treatment
  
• Toxic Shock Syndrome
  
• Overview
  
• Treatment
  
• Yeast Infections
  
• Overview
  
• Treatment
  
• Market Size and Growth
  
• Geographical Market Analysis
  
• Research and Development
  
  
  • Ampligen
    
  • Bevirimat
    
  • Boceprevir
    
  • Clevudine
    
  • Elvitegravir
    
  • GS 9137
    
  • Hepaconda
    
  • IC41
    
  • IDX899
    
  • Loctero
    
  • R7128
    
  • RDEA806
    
  • SPO1A
    
  • Telaprevir
    
  • TMC278
    
  • Vicriviroc
    
  • VRX496
  
  
• Competitive Market

• Overview
  
• Statistics
  
• Contraception
  
• Overview
  
• Treatment
  
• Oral Contraceptives
  
• Depo-Provera
  
• Birth Control Patch
  
• Vaginal Ring
  
• Emergency Contraception and Early Option
  
• Implant
  
• IUD
  
• Endometriosis
  
• Overview
  
• Treatment
  
• Fibroids
  
• Overview
  
• Treatment
  
• Infertility
  
• Overview
  
• Treatment
  
• Menopause
  
• Overview
  
• Treatment
  
• Menstrual Disorders
  
• Amenorrhea
  
• Treatment
  
• Dysmenorrhea
  
• Treatment
  
• Sexual Dysfunction
  
• Overview
  
• Treatment
  
• Market Size and Growth
  
• Geographical Market Analysis
  
• Research and Development
  
• Alista
  
• LibiGel
  
• NOMAC/E2
  
• Ophena
  
• Org 36286
  
• Competitive Market

• Overview
  
• Prevalence
  
• Prevention
  
• Treatment
  
• Market Size and Growth
  
• Geographical Market Analysis
  
• Research and Development
  
• Arzoxifene
  
• Denosumab
  
• Fablyn
  
• MK-0822 (Odanacatib)
  
• Preos
  
• SUN E3001
  
• Viviant
  
• Competitive Market

• Overview
  
• Incidence and Prevalence
  
• Cystitis
  
• Overview
  
• Treatment
  
• Incontinence
  
• Overview
  
• Treatment
  
• Overactive Bladder
  
• Treatment
  
• Alternative Treatments
  
• Interstitial Cystitis
  
• Overview
  
• Treatment
  
• Market Size and Growth
  
• Geographical Market Analysis
  
• Research and Development
  
• Oxybutynin Gel
  
• Anturol
  
• PSD503
  
• Competitive Market

• Overview
  
• Total Market Size and Forecast
  
• Market Analysis

• Overview

• Table 1-1: The World Market Women’s Disorders 2006-2013
  
• Figure 1-1: The World Market Women’s Disorders 2006-2013

• Table 2-1: World Life Expectancy at Birth in Selected Countries by Sex, 2007
  
• Figure 2-1: Female Advantage in Life Expectancy at Birth in Selected Countries, 2007 (Difference, in Years, between Females and Males)
  
• Table 2-2: World Population Growth, by Total World Population and
  Selected Country or Regions and Selected Characteristics
  
• Figure 2-2: World Population Growth by Sex 2000, 2005, 2010,
  2020, 2025 (in millions)
  
• Figure 2-3: United States Population Growth by Sex 2000, 2005,
  2010, 2020, 2025 (in millions)
  
• Figure 2-4: Five Major European Countries* Population
  Growth by Sex 2000, 2005, 2010, 2020, 2025 (in millions)
  
• Figure 2-5: Japan Population Growth by Sex 2000, 2005, 2010,
  2020, 2025 (in millions)
  
• Table 2-3: World Female Population Growth by Selected Country or Regions
  and Selected Age Group
  
• Figure 2-6: World Female Population Growth by Selected Age Group 2000,
  2005, 2010, 2020, 2025 (in millions)
  
• Figure 2-7: United States Female Population Growth by Selected Age
  Group 2000, 2005, 2010, 2020, 2025 (in millions)
  
• Figure 2-8: Five Major European Countries* Female Population Growth by
  Selected Age Group 2000, 2005, 2010, 2020, 2025 (in millions)
  
• Figure 2-9: Japan Female Population Growth by Selected Age
  Group 2000, 2005, 2010, 2020, 2025 (in millions)

• Table 3-1: Estimated Female Prevalence of Autoimmune Diseases by
  Type and Geographical Distribution, Estimated 2008
  
• Table 3-2: The World Market for Autoimmune Disease Drugs for
  Women 2006-2013
  
• Figure 3-1: The World Market for Autoimmune Disease Drugs for
  Women 2006-2013
  
• Table 3-3: The World Market for Autoimmune Disease Drugs for Women
  by Disease Type 2006-2013
  
• Figure 3-4: The World Market for Autoimmune Disease Drugs for
  
• Table 3-4 Women, Revenues by Disease Type 2006-2013
  
• Figure 3-3: The World Market for Autoimmune Disease Drugs for
  
• Figure 3-4: The World Market for Autoimmune Disease Drugs for Women,
  Market Share by Disease Type 2013
  
• Table 3-8: The World Market for Autoimmune Disease Drugs for
  
• Women Market Analysis by Region/Country, 2008
  
• Figure 3-5: The World Market for Autoimmune Disease Drugs for Women
  Market Analysis by Region/Country, 2008
  
• Table 3-5 Select Products in Development for Chronic Fatigue
  Syndrome 2008
  
• Table 3-6: Select Products in Development for Fibromyalgia 2008
  
• Table 3-7: Select Products in Development for Rheumatoid Arthritis 2008
  
• Table 3-8: Products in Development for Sjogren’s Syndrome, 2008
  
• Table 3-9: Products in Development for Systemic Lupus Erythematosus 2008
  
• Table 3-6: The World Market for Autoimmune Disease Drugs for Women
  Revenues and Market Share by Supplier 2008
  
• Figure 3-10: The World Market for Autoimmune Disease Drugs
  for Women Market Share by Leading Supplier 2008

• Table 4-1: Estimated Incidence of Female Cancers and Mortality by
  Type and Geographical Distribution, Estimated 2008
  
• Table 4-2: The World Market for Cancer Drugs for Women 2006-2013
  
• Figure 4-1: The World Market for Cancer Drugs for Women 2006-2013
  
• Table 4-3: The World Market for Cancer Drugs for Women by
  Disease Type 2006-2013
  
• Figure 4-2: The World Market for Cancer Drugs for Women, Revenues
  by Cancer Type 2006-2013
  
• Figure 4-3: The World Market for Cancer Drugs for Women, Market
  Share by Cancer Type 2008
  
• Figure 4-4: The World Market for Cancer Drugs for Women, Market
  Share by Cancer Type 2013
  
• Table 4-4: The World Market for Cancer Drugs for Women Market Analysis by Region/Country, 2008
  
• Figure 4-5: The World Market for Cancer Drugs for Women Market Analysis by Region/Country, 2008
  
• Table 4-5: Select Products in Development for Breast Cancer 2008
  
• Table 4-6: Select Products in Development for Cervical Cancer 2008
  
• Table 4-7: Select Products in Development for Endometrial Cancer 2008
  
• Table 4-8: Select Products in Development for Ovarian Cancer 2008
  
• Table 4-9: Select Products in Development for Vaginal Cancer, 2008
  
• Table 4-6: The World Market for Cancer Drugs for Women Revenues
  and Market Share by Supplier 2008
  
• Figure 4-10: The World Market for Cancer Drugs for Women Market
  Share by Leading Supplier 2008

• Table 5-1: Estimated Female Incidence and Prevalence Gynecological and Sexually Transmitted Diseases by Type and Geographical Distribution, 2007/2008
  
• Table 5-2: Gynecological and Sexually Transmitted Diseases Related
  Epidemiologic Data, Five Year Average 2007/2008 Average
  
• Table 5-3: The World Market for Gynecological Infections and Sexually
  Transmitted Diseases for Women 2006-2013
  
• Figure 5-1: The World Market for Gynecological Infections and Sexually
  Transmitted Diseases for Women 2006-2013
  
• Table 5-4: The World Market for Gynecological Infections and Sexually
  Transmitted Diseases for Women by Disease Type 2006-2013
  
• Figure 5-2: The World Market for Gynecological Infections and Sexually
  Transmitted Diseases for Women, Revenues by Disease Type 2006-2013
  
• Figure 5-3: The World Market for Gynecological Infections and Sexually
  Transmitted Diseases for Women, Market Share by Disease Type 2008
  
• Figure 5-4: The World Market for Gynecological Infections and Sexually
  Transmitted Diseases for Women, Market Share by Disease Type 2013
  
• Table 5-5: The World Market for Gynecological Infections and Sexually
  Transmitted Diseases for Women Market Analysis by Region/Country, 2008
  
• Figure 5-5: The World Market for Gynecological Infections and Sexually
  Transmitted Diseases for Women Market Analysis by Region/Country, 2008
  
• Table 5-6: Select Products in Development for AIDS/HIV 2008
  
• Table 5-7: Select Products in Development for Cervical Dysplagia 2008
  
• Table 5-8: Select Products in Development for Condyloma Acumenta 2008
  
• Table 5-9: Select Products in Development for Genital Herpes 2008
  
• Table 5-10: Select Products in Development for Hepatitis, 2008
  
• Table 5-6: The World Market for Gynecological Infections and
  Sexually Transmitted Diseases for Women Revenues and Market
  Share by Supplier 2008
  
• Figure 5-11: The World Market for Gynecological Infections and Sexually Transmitted Diseases for Women Market Share by Leading Supplier 2008

• Table 6-1: Estimated World and U.S. Female Incidence and Prevalence of
  Hormone-Related Disorders and Indications by Type, Five Year
  Average 2007/2008
  
• Table 6-2: Estimated World and U.S. Contraceptive Use by Method, Five Year
  Average 2007/2008
  
• Table 6-3: Selected Oral Contraceptives Available 2007/2008
  
• Table 6-4: Selected Hormone Replacement Therapies
  
• Table 6-5: The World Market for Hormone-related Disorders
  for Women, 2006-2013
  
• Figure 6-1: The World Market for Hormone-related Disorders for Women 2006-2013
  
• Table 6-6: The World Market for Hormone-related Disorders for Women by Disorder Type 2006-2013
  
• Figure 6-2: The World Market for Hormone-related Disorders for
  Women, Revenues by Disorder Type 2006-2013
  
• Figure 6-3: The World Market for Hormone-related Disorders for
  Women, Market Share by Disorder Type 2008
  
• Figure 6-4: The World Market for Hormone-related Disorders for
  Women, Market Share by Disorder Type 2013
  
• Table 6-7: The World Market for Hormone-related Disorders for
  Women Market Analysis by Region/Country, 2008
  
• Figure 6-5: The World Market for Hormone-related Disorders for
  Women Market Analysis by Region/Country, 2008
  
• Table 6-8: Select Products in Development for Oral Contraceptives 2008
  
• Table 6-9: Select Products in Development for Endometriosis 2008
  
• Table 6-10: Select Products in Development for Infertility 2008
  
• Table 6-11: Select Products in Development for Menopause 2008
  
• Table 6-12: Select Products in Development for Menstrual Disorders 2008
  
• Table 6-13: Select Products in Development for Sexual Dysfunction 2008
  
• Table 6-14: The World Market for Hormone-related Disorders for
  Women Revenues and Market Share by Supplier 2008
  
• Figure 6-6: The World Market for Hormone-related Disorders for
  Women Market Share by Leading Supplier 2008

• Table 7-1: Estimated Female Prevalence of Osteoporosis by Type and
  Geographical Distribution, Average 2007/2008
  
• Table 7-2: The World Market for Osteoporosis Treatments for Women
  2006-2013
  
• Figure 7-1: The World Market for Osteoporosis Treatments for
  Women 2006-2013
  
• Table 7-3: The World Market for Osteoporosis Treatments for
  Women Market Analysis by Region/Country, 2008
  
• Figure 7-2: The World Market for Osteoporosis Treatments for
  Women Market Analysis by Region/Country, 2008
  
• Table 7-4: Select Products in Development for Osteoporosis Drugs 2008
  
• Table 7-5: The World Market for Osteoporosis Treatments for
  Women Revenues and Market Share by Supplier 2008
  
• Figure 7-3: The World Market for Osteoporosis Treatments for
  Women Market Share by Leading Supplier 2008

• Table 8-1: Estimated Female Incidence and Prevalence of Urinary
  Bladder Disorders by Type and Geographical Distribution, Average 2007/2008
  
• Table 8-2: Medications That Can Affect Urination
  
• Table 8-3: The World Market for Urinary Bladder Disorders
  for Women 2006-2013
  
• Figure 8-1: The World Market for Urinary Bladder Disorders
  for Women 2006-2013
  
• Table 8-4: The World Market for Urinary Bladder Disorders
  for Women by Disease Type 2006-2013
  
• Figure 8-2: The World Market for Urinary Bladder Disorders
  for Women, Revenues by Disease Type 2006-2013
  
• Figure 8-3: The World Market for Urinary Bladder Disorders for
  Women, Market Share by Disease Type 2008
  
• Figure 8-4: The World Market for Urinary Bladder Disorders for
  Women, Market Share by Disease Type 2013
  
• Table 8-5: The World Market for Urinary Bladder Disorders for
  Women Market Analysis by Region/Country, 2008
  
• Figure 8-5: The World Market for Urinary Bladder Disorders for
  Women Market Analysis by Region/Country, 2008
  
• Table 8-6: Select Products in Development for Urinary Disorders 2008
  
• Table 8-7: The World Market for Urinary Bladder Disorders for
  Women Revenues and Market Share by Supplier 2008
  
• Figure 8-6: The World Market for Urinary Bladder Disorders for
  Women Market Share by Leading Supplier 2008

• Table 9-1: The World Market for Women’s Disorders, Revenues
  by Product Segment 2006-2013
  
• Figure 9-1: The World Market for Women’s Disorders, Revenues
  by Product Segment 2006-2013

• Table 10-1: The World Market for Women’s Disorders, Revenues
  and Market Share by Supplier 2008
  
• Figure 10-2: The World Market for Women’s Disorders, Top
  Ten Suppliers by Percent, 2008

Abstract

• Autoimmune diseases
• Cancer
• Gynecological and Sexually Transmitted Diseases
• Hormones
• Osteoporosis
• Urinary Disorders

Women's Health: Worldwide Prescription Drug Markets, represents the fourth time that Kalorama Information has tackled the women's health pharmaceutical market. Revenues from these segments are not reported in total, as certain segments affect both men and women. The analysis and market data in this report estimate revenues associated with therapeutics for women only. Segmentation within each category is by major drug type and by geographic region (U.S., Europe, Japan, ROW). All market data pertain to the U.S. market at the manufacturers’ level. Data are expressed in current U.S. dollars. The base year for data was 2007. forecast data are provided for each of the years 2009 through 2013. Historical, base year, and forecast data are provided for each market segment. Market shares are provided for each market segment for the 2007 base year.

In addition to market data, the report contains extensive product pipeline information, competitor profiles, and discussions of the major industry issues and trends shaping the market.

The information and analysis presented in this report are based on an extensive survey of senior management in the prescription women’s health drug industry. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals. Key information from published literature was used to conduct interviews with over 40 industry executives and product managers to validate and obtain expert opinion on current and future trends in the women’s health industry. Interviews were also used to confirm and/or adjust market size and market share estimates, as well as in formulating market projections.

Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.